USF-LVHN SELECT
Discrepancy Between Liquid Biopsy and Tumor Next-Generation Sequencing Due to Low Tumor Fraction in a Patient With Lung Adenocarcinoma.
Publication/Presentation Date
9-1-2024
Abstract
Tumor next-generation sequencing (NGS) is the gold standard molecular testing for driver genomic alterations in patients with advanced non-small cell lung cancer (NSCLC). However, it requires a biopsy, which is an invasive procedure. In contrast, a liquid biopsy is a minimally invasive test that measures circulating tumor DNA (ctDNA) in the plasma and can be also used for molecular profiling. We report a case of a patient with stage IV metastatic lung adenocarcinoma with a negative liquid biopsy for tumor-derived genomic alterations but positive tissue NGS for mutations, including a driver
Volume
16
Issue
9
First Page
70119
Last Page
70119
ISSN
2168-8184
Published In/Presented At
Baker, M. C., Rose, T. A., & Pellini, B. (2024). Discrepancy Between Liquid Biopsy and Tumor Next-Generation Sequencing Due to Low Tumor Fraction in a Patient With Lung Adenocarcinoma. Cureus, 16(9), e70119. https://doi.org/10.7759/cureus.70119
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
39449891
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article